149 related articles for article (PubMed ID: 35034026)
1. Prognostic Potential of METTL7B in Glioma.
Fu R; Luo X; Ding Y; Guo S
Neuroimmunomodulation; 2022; 29(3):186-201. PubMed ID: 35034026
[TBL] [Abstract][Full Text] [Related]
2. A Whole Exon Screening-Based Score Model Predicts Prognosis and Immune Checkpoint Inhibitor Therapy Effects in Low-Grade Glioma.
Luo C; Wang S; Shan W; Liao W; Zhang S; Wang Y; Xin Q; Yang T; Hu S; Xie W; Xu N; Zhang Y
Front Immunol; 2022; 13():909189. PubMed ID: 35769464
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the Clinical Significance of PD-1/PD-Ls Expression and Methylation in Patients With Low-Grade Glioma.
Mei J; Cai Y; Xu R; Yang X; Zhou W; Wang H; Liu C
Technol Cancer Res Treat; 2021; 20():15330338211011970. PubMed ID: 33955303
[TBL] [Abstract][Full Text] [Related]
4. METTL7B is a novel prognostic biomarker of lower-grade glioma based on pan-cancer analysis.
Jiang Z; Yin W; Zhu H; Tan J; Guo Y; Xin Z; Zhou Q; Cao Y; Wu Z; Kuang Y; Li C; Xie D; Huang H; Zhao M; Jiang X; Wang L; Ren C
Cancer Cell Int; 2021 Jul; 21(1):383. PubMed ID: 34281539
[TBL] [Abstract][Full Text] [Related]
5. High Level of METTL7B Indicates Poor Prognosis of Patients and Is Related to Immunity in Glioma.
Xiong Y; Li M; Bai J; Sheng Y; Zhang Y
Front Oncol; 2021; 11():650534. PubMed ID: 33996568
[TBL] [Abstract][Full Text] [Related]
6. ECM2, a prognostic biomarker for lower grade glioma, serves as a potential novel target for immunotherapy.
Cheng X; Liu Z; Liang W; Zhu Q; Wang C; Wang H; Zhang J; Li P; Gao Y
Int J Biochem Cell Biol; 2023 May; 158():106409. PubMed ID: 36997057
[TBL] [Abstract][Full Text] [Related]
7. Characterization of METTL7B to Evaluate TME and Predict Prognosis by Integrative Analysis of Multi-Omics Data in Glioma.
Chen X; Li C; Li Y; Wu S; Liu W; Lin T; Li M; Weng Y; Lin W; Qiu S
Front Mol Biosci; 2021; 8():727481. PubMed ID: 34604305
[TBL] [Abstract][Full Text] [Related]
8. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
9. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
10. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R
J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420
[TBL] [Abstract][Full Text] [Related]
11. Integrated machine learning methods identify FNDC3B as a potential prognostic biomarker and correlated with immune infiltrates in glioma.
Wang X; Huang Y; Li S; Zhang H
Front Immunol; 2022; 13():1027154. PubMed ID: 36275754
[TBL] [Abstract][Full Text] [Related]
12. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.
Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801
[TBL] [Abstract][Full Text] [Related]
13. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124
[TBL] [Abstract][Full Text] [Related]
14. Exploring the prognostic potential of m6A methylation regulators in low-grade glioma: implications for tumor microenvironment modulation.
Wu H; Chen S; Hu Z; Ge R; Ma L; You C; Huang Y
Eur J Med Res; 2024 Jan; 29(1):19. PubMed ID: 38173044
[TBL] [Abstract][Full Text] [Related]
15. Integrative analysis regarding the correlation between GAS2 family genes and human glioma prognosis.
Zhao C; Zhang N; Cui X; Zhang X; Ren Y; Su C; He J; Zhang W; Sun X; Yang J; Gao X
Cancer Med; 2021 Apr; 10(8):2826-2839. PubMed ID: 33713047
[TBL] [Abstract][Full Text] [Related]
16. A prognostic signature of five pseudogenes for predicting lower-grade gliomas.
Liu B; Liu J; Liu K; Huang H; Li Y; Hu X; Wang K; Cao H; Cheng Q
Biomed Pharmacother; 2019 Sep; 117():109116. PubMed ID: 31247469
[TBL] [Abstract][Full Text] [Related]
17. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
18. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
19. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.
Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z
Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479
[TBL] [Abstract][Full Text] [Related]
20. A risk signature of four aging-related genes has clinical prognostic value and is associated with a tumor immune microenvironment in glioma.
Luo H; Tao C; Long X; Huang K; Zhu X
Aging (Albany NY); 2021 Jun; 13(12):16198-16218. PubMed ID: 34114970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]